ATE86867T1 - Thrombolytische zusammensetzung enthaltender gewebetyp, plasminogenaktivatoren oder derivate davon. - Google Patents

Thrombolytische zusammensetzung enthaltender gewebetyp, plasminogenaktivatoren oder derivate davon.

Info

Publication number
ATE86867T1
ATE86867T1 AT90310288T AT90310288T ATE86867T1 AT E86867 T1 ATE86867 T1 AT E86867T1 AT 90310288 T AT90310288 T AT 90310288T AT 90310288 T AT90310288 T AT 90310288T AT E86867 T1 ATE86867 T1 AT E86867T1
Authority
AT
Austria
Prior art keywords
salt
tissue type
derivatives
type containing
plasminogen activators
Prior art date
Application number
AT90310288T
Other languages
English (en)
Inventor
Yokio Shimazaki
Miyuki Kawashima
Masahiko Ishibashi
Ryo Tanaka
Kiyoshi Sakai
Hisahiro Ishiwari
Original Assignee
Mitsui Toatsu Chemicals
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsui Toatsu Chemicals, Mochida Pharm Co Ltd filed Critical Mitsui Toatsu Chemicals
Application granted granted Critical
Publication of ATE86867T1 publication Critical patent/ATE86867T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT90310288T 1989-09-21 1990-09-20 Thrombolytische zusammensetzung enthaltender gewebetyp, plasminogenaktivatoren oder derivate davon. ATE86867T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24331089 1989-09-21
EP90310288A EP0419252B1 (de) 1989-09-21 1990-09-20 Thrombolytische Zusammensetzung enthaltender Gewebetyp, Plasminogenaktivatoren oder Derivate davon

Publications (1)

Publication Number Publication Date
ATE86867T1 true ATE86867T1 (de) 1993-04-15

Family

ID=17101932

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90310288T ATE86867T1 (de) 1989-09-21 1990-09-20 Thrombolytische zusammensetzung enthaltender gewebetyp, plasminogenaktivatoren oder derivate davon.

Country Status (15)

Country Link
US (1) US6051223A (de)
EP (1) EP0419252B1 (de)
JP (1) JP2520975B2 (de)
KR (1) KR930008908B1 (de)
CN (1) CN1041799C (de)
AT (1) ATE86867T1 (de)
BR (1) BR9004692A (de)
CA (1) CA2025317C (de)
DE (1) DE69001110T2 (de)
DK (1) DK0419252T3 (de)
ES (1) ES2054263T3 (de)
FI (1) FI104953B (de)
GR (1) GR3007396T3 (de)
NO (1) NO904119L (de)
NZ (1) NZ235298A (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207151B1 (en) * 1989-09-21 2001-03-27 Mitsui Chemicals Inc. Aqueous solution of t-PA
US5272076A (en) * 1991-06-13 1993-12-21 Eli Lilly And Company Compounds and methods for treatment of thromboembolic disorders using an adduct of t-PA
US6527979B2 (en) * 1999-08-27 2003-03-04 Corazon Technologies, Inc. Catheter systems and methods for their use in the treatment of calcified vascular occlusions
JP4395540B2 (ja) * 2006-03-27 2010-01-13 農工大ティー・エル・オー株式会社 トリプレニルフェノール化合物及びトリプレニルフェノール化合物の製造方法並びに、血栓溶解促進剤
CA2876177C (en) 2012-06-11 2022-06-14 The Cleveland Clinic Foundation Treatment and prevention of cardiovascular disease and thrombosis
CN103191054B (zh) * 2013-04-19 2015-05-27 范克 一种肝素钠封管注射液及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2310133A2 (fr) * 1975-05-05 1976-12-03 Fabre Sa Pierre Nouveau medicament comportant un activateur du plasminogene perfectionne
JPS52145591A (en) * 1976-05-28 1977-12-03 Kanebo Ltd Stabilization of urokinase
JPS5467089A (en) * 1977-11-07 1979-05-30 Dainippon Pharmaceut Co Ltd Urokinase composition
JPS5568290A (en) * 1978-11-16 1980-05-22 Kanebo Ltd Stabilization of urokinase
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
JPS60158116A (ja) * 1984-01-30 1985-08-19 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
JPS60158117A (ja) * 1984-01-30 1985-08-19 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
JPS60184026A (ja) * 1984-03-01 1985-09-19 Asahi Chem Ind Co Ltd 組織プラスミノ−ゲン・アクチベ−タ−の溶解補助方法
JPS60181028A (ja) * 1984-02-29 1985-09-14 Asahi Chem Ind Co Ltd 組織プラスミノ−ゲン・アクチベ−タ−の溶解補助法
WO1986005095A1 (en) * 1985-03-06 1986-09-12 Survival Technology, Inc. t-PA COMPOSITION AND METHOD OF GETTING INTO BLOOD STREAM
DE3512910A1 (de) * 1985-04-11 1986-10-16 Behringwerke Ag, 3550 Marburg Verfahren zur reinigung von plasminogenaktivatoren
DE3512909A1 (de) * 1985-04-11 1986-10-23 Behringwerke Ag, 3550 Marburg Verfahren zur bestimmung von plasminogenaktivatoren (pa)
DE3512908A1 (de) * 1985-04-11 1986-10-23 Behringwerke Ag, 3550 Marburg Gewebe-plasminogenaktivator (t-pa) enthaltendes mittel
JPH0669960B2 (ja) * 1985-11-22 1994-09-07 エーザイ株式会社 水溶性を増加したｔＰＡ含有医薬組成物
ATE83153T1 (de) * 1985-09-10 1992-12-15 Eisai Co Ltd Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung.
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
JPS62120321A (ja) * 1985-11-20 1987-06-01 Eisai Co Ltd ｔＰＡ含有医薬組成物
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
JPH0678241B2 (ja) * 1986-04-02 1994-10-05 エーザイ株式会社 ｔＰＡ医薬組成物
JPS62292729A (ja) * 1986-06-12 1987-12-19 Toyobo Co Ltd ヒト子宮組織由来プラスミノ−ゲン活性化因子製剤
US4857320A (en) * 1987-02-19 1989-08-15 Monsanto Company Method of enhancing the solubility of tissue plasminogen activator
DE3718889A1 (de) * 1987-06-05 1988-12-22 Behringwerke Ag Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
JP2708749B2 (ja) * 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
JPH06226234A (ja) * 1993-02-01 1994-08-16 Shojiro Takeuchi 産業廃棄物の炭化処理方法
JPH06236332A (ja) * 1993-02-09 1994-08-23 Oki Electric Ind Co Ltd プログラムローディング装置
JPH06259221A (ja) * 1993-03-05 1994-09-16 Tokyo Electric Co Ltd 画面表示器を備えた情報処理装置
JPH06281326A (ja) * 1993-03-30 1994-10-07 Shibaura Eng Works Co Ltd 洗浄物の乾燥方法

Also Published As

Publication number Publication date
JP2520975B2 (ja) 1996-07-31
DK0419252T3 (da) 1993-04-19
FI104953B (fi) 2000-05-15
EP0419252A1 (de) 1991-03-27
CA2025317A1 (en) 1991-03-22
AU619697B2 (en) 1992-01-30
NO904119L (no) 1991-03-22
NO904119D0 (no) 1990-09-20
BR9004692A (pt) 1991-09-10
ES2054263T3 (es) 1994-08-01
KR930008908B1 (ko) 1993-09-17
GR3007396T3 (de) 1993-07-30
JPH0418032A (ja) 1992-01-22
FI904617A0 (fi) 1990-09-19
CA2025317C (en) 1996-05-07
AU6246790A (en) 1991-03-28
CN1050321A (zh) 1991-04-03
NZ235298A (en) 1992-12-23
KR910005883A (ko) 1991-04-27
CN1041799C (zh) 1999-01-27
DE69001110T2 (de) 1993-06-24
EP0419252B1 (de) 1993-03-17
DE69001110D1 (de) 1993-04-22
US6051223A (en) 2000-04-18

Similar Documents

Publication Publication Date Title
DE60036017T2 (de) Verfahren zur thrombolyse durch lokale behandlung mit reversibel inaktiviertem, angesäuertem plasmin
FI875533A0 (fi) Insulinpreparat foer non-parenteral dosering.
NO871199D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater med langvarige frigjoeringsegenskaper.
FI882605A0 (fi) Menetelmä, jonka avulla voidaan valmistaa suuren spesifisen tilavuusaktiivisuuden omaavaa liuosta proteiinista, jolla on kudosplasminogeeniaktivaattori(t-PA)-aktiivisuutta
DE3680271D1 (de) Thrombolytische zusammensetzung und verfahren zu deren herstellung.
KR880013572A (ko) 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도
ATE86867T1 (de) Thrombolytische zusammensetzung enthaltender gewebetyp, plasminogenaktivatoren oder derivate davon.
CH637992A5 (de) Verfahren zur herstellung eines komplexes aus streptokinase und einer leichten (b) plasmin-kettenfraktion mit einem aktiven serinprotease-zentrum.
ATE82132T1 (de) Auf ligninsulfonat aufgebautes pharmazeutisches mittel mit einer atithrombose-aktivitaet.
PT89802A (pt) Processo para a preparacao de uma composicao farmaceutica, contendo o factor xiii de coagulacao do sangue humano, para a prevencao da hemorragia intraventricular em criancas permaturas
FI91710B (fi) Menetelmä injektoitavan käyttövalmiin, säilytystä kestävän, steriilin antrasykliiniglykosidiliuoksen valmistamiseksi
FI98891B (fi) Menetelmä vesiliuoksen proteiinipitoisuuden lisäämiseksi
Aoki et al. Potentiation by synthetic fibrinolytic agents of vascular activator-and urokinase-induced lysis of human plasma clots as demonstrated by thrombelastography
DE68905577D1 (de) Doxorubicin-loesungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee